Eutilex (KOSDAQ:263050.KQ)

1:30 PM - 1:45 PM, Monday, June 3, 2019 ・ Theater 4
Eutilex is a leader in discovery and development of innovative immune-oncology products, such as the EU102, the worldwide unique regulatory T cell converting antibody amounting a strong anti-cancer effect in vivo and the phase 2-entering clinical-stage 4-1BB CTL T cell therapy that has proven to have one of the industry’s best safety records and exhibited encouraging sings of efficacy in also solid tumors. Eutilex is progressing in the development of these businesses globally.
Ticker:
263050.KQ
Exchange:
KOSDAQ
Company Type:
Company Website:
Company HQ State:
Not Provided.
Company HQ Country:
Korea - South Korea
Year Founded:
2015
Main Therapeutic Focus:
Lead Product in Development:
4-1BB CTL T cell therapy
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
3